Showing results (11-20 of 297) with videos related to
Sort By:
Pageof 30
Oncology (Williston Park, N.Y.)|June 13, 2003
Irinotecan treatment in cancer patients with UGT1A1 polymorphismsFederico Innocenti, Mark J RatainClinical and Translational Science|August 26, 2025
Strengthening the Food and Drug Administration Office of Clinical Pharmacology's Labeling AuthorityMark J Ratain, Garth W StrohbehnNature Reviews. Cancer|April 25, 2006
Measuring response in a post-RECIST world: from black and white to shades of greyLaura C Michaelis, Mark J RatainCA: a Cancer Journal for Clinicians|January 17, 2009
Pharmacogenetics and pharmacogenomics of anticancer agentsR Stephanie Huang, Mark J RatainEuropean Journal of Cancer (Oxford, England : 1990)|December 9, 2008
Optimising the design of phase II oncology trials: the importance of randomisationMark J Ratain, Daniel J SargentMolecular Oncology|February 11, 2012
Germline pharmacogenomics in oncology: decoding the patient for targeting therapyPeter H O'Donnell, Mark J RatainClinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2010
Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology productsSoonmo Peter Kang, Mark J RatainClinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2012
Might cigarettes be a "smoking gun" to reduce taxane myelotoxicity?Lionel D Lewis, Mark J RatainEuropean Journal of Cancer (Oxford, England : 1990)|October 8, 2023
Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?Mark J Ratain, Garth W StrohbehnClinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2007
Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialtiesLaura C Michaelis, Mark J RatainPageof 30